HI Jack - I agree the E/M visit, DXA and FRAX scores are important. Fortunately we have injectables like denosumab and new ones underinvestigation. I have a main problem with generic bisphosphonates because of data on their tolerability and since no generic is ever investigated in patients before it comes to market I have concern about their efficacy